Cargando…

Hypertensive Retinopathy Secondary to Anlotinib Treatment

PURPOSE: We report a case of a middle-aged woman who developed hypertensive retinopathy following oral administration of Anlotinib. OBSERVATIONS: A 48-year-old woman presented to our hospital with sudden painless loss of vision in both eyes combined with headache, nausea, and vomiting following oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaohua, Peng, Li, Xie, Qing, Wu, Qingjing, Sheng, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291867/
https://www.ncbi.nlm.nih.gov/pubmed/32581802
http://dx.doi.org/10.3389/fphar.2020.00843
_version_ 1783545985075511296
author Zhang, Xiaohua
Peng, Li
Xie, Qing
Wu, Qingjing
Sheng, Xia
author_facet Zhang, Xiaohua
Peng, Li
Xie, Qing
Wu, Qingjing
Sheng, Xia
author_sort Zhang, Xiaohua
collection PubMed
description PURPOSE: We report a case of a middle-aged woman who developed hypertensive retinopathy following oral administration of Anlotinib. OBSERVATIONS: A 48-year-old woman presented to our hospital with sudden painless loss of vision in both eyes combined with headache, nausea, and vomiting following oral administration of Anlotinib. This drug is often used to control cancer progression. Due to the deterioration of her blood pressure, which reached 167/113 mm Hg, Anlotinib was discontinued and the blood pressure was controlled by hypertension medications. This normalized her blood pressure, alleviated headache, and restored her vision. She visited our eye department 37 days later for eye check-up. The best-corrected visual acuities was 0.3 in the right eye and 0.4 in the left eye. The fundus examinations revealed a clear boundary of the optic papilla with significant stellate exudation in the macular area. The posterior pole of the retina displayed high hemorrhage, with a cotton-wool spot appearance. Optical coherence tomography (OCT) revealed atrophy in the outer segment of macular area, and hard exudations in retinal layers. Based on these findings, hypertensive retinopathy was diagnosed, as a secondary complication of Anlotinib. CONCLUSIONS AND SIGNIFICANCE: Anlotinib can induce hypertensive retinopathy. Patients receiving this drug should be closely monitored for potential complications.
format Online
Article
Text
id pubmed-7291867
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72918672020-06-23 Hypertensive Retinopathy Secondary to Anlotinib Treatment Zhang, Xiaohua Peng, Li Xie, Qing Wu, Qingjing Sheng, Xia Front Pharmacol Pharmacology PURPOSE: We report a case of a middle-aged woman who developed hypertensive retinopathy following oral administration of Anlotinib. OBSERVATIONS: A 48-year-old woman presented to our hospital with sudden painless loss of vision in both eyes combined with headache, nausea, and vomiting following oral administration of Anlotinib. This drug is often used to control cancer progression. Due to the deterioration of her blood pressure, which reached 167/113 mm Hg, Anlotinib was discontinued and the blood pressure was controlled by hypertension medications. This normalized her blood pressure, alleviated headache, and restored her vision. She visited our eye department 37 days later for eye check-up. The best-corrected visual acuities was 0.3 in the right eye and 0.4 in the left eye. The fundus examinations revealed a clear boundary of the optic papilla with significant stellate exudation in the macular area. The posterior pole of the retina displayed high hemorrhage, with a cotton-wool spot appearance. Optical coherence tomography (OCT) revealed atrophy in the outer segment of macular area, and hard exudations in retinal layers. Based on these findings, hypertensive retinopathy was diagnosed, as a secondary complication of Anlotinib. CONCLUSIONS AND SIGNIFICANCE: Anlotinib can induce hypertensive retinopathy. Patients receiving this drug should be closely monitored for potential complications. Frontiers Media S.A. 2020-06-05 /pmc/articles/PMC7291867/ /pubmed/32581802 http://dx.doi.org/10.3389/fphar.2020.00843 Text en Copyright © 2020 Zhang, Peng, Xie, Wu and Sheng http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Xiaohua
Peng, Li
Xie, Qing
Wu, Qingjing
Sheng, Xia
Hypertensive Retinopathy Secondary to Anlotinib Treatment
title Hypertensive Retinopathy Secondary to Anlotinib Treatment
title_full Hypertensive Retinopathy Secondary to Anlotinib Treatment
title_fullStr Hypertensive Retinopathy Secondary to Anlotinib Treatment
title_full_unstemmed Hypertensive Retinopathy Secondary to Anlotinib Treatment
title_short Hypertensive Retinopathy Secondary to Anlotinib Treatment
title_sort hypertensive retinopathy secondary to anlotinib treatment
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291867/
https://www.ncbi.nlm.nih.gov/pubmed/32581802
http://dx.doi.org/10.3389/fphar.2020.00843
work_keys_str_mv AT zhangxiaohua hypertensiveretinopathysecondarytoanlotinibtreatment
AT pengli hypertensiveretinopathysecondarytoanlotinibtreatment
AT xieqing hypertensiveretinopathysecondarytoanlotinibtreatment
AT wuqingjing hypertensiveretinopathysecondarytoanlotinibtreatment
AT shengxia hypertensiveretinopathysecondarytoanlotinibtreatment